Integrated treatment of malignant tumour pleura involvement accompanied with exudative pleurisy
SUBSTANCE: integrated treatment of malignant tumour pleura involvement accompanied with exudative pleurisy is ensured with argon-plasma electrocoagulation of pleura at power 60-90 Wt and argon consumption 2.0-2.4 l/min followed with intraoperative photodynamic therapy. A photosensitiser is Photoditasine dosed 1.5 mg/kg. The irradiation involves diode laser of wavelength 662 nm and power density 300 mWt/cm2, at total energy dose 400 J/cm2. In addition, it is combined with hyperthermic intrapleural chemoperfsion of cisplatin 100 mg in 1500-3000 ml of 0.9 % sodium chloride solution at temperature 42°C within 60 minutes at feed rate 1200 ml/min.
EFFECT: reduced tumour weight, terminated exudation and protein loss, reduced inflammation, intoxication and pain syndrome, local and systemic cytostatic action of cisplatin.
Malignant neoplasms remain acute medical and social problem. In the structure of mortality Russia malignant neoplasms ranked third and account for 13%. The majority of patients with malignant tumors is more than 2 million people, or 1.4% of the population of the country. Who experts believe that the trend towards growth in cancer incidence will continue, with up to 90% of patients some localizations neoplastic processes will be incurable. In Russia from cancer annually kills more than 300 thousand patients, 70% of them need palliative care. Remaining unresolved at present the problem of early diagnosis of lung cancer leads to the fact that the majority of patients (over 75%) is in specialized medical institutions in the III-IV stages of the disease. In this regard, the provision of palliative care to patients with common forms of malignant neoplasms is one of the major challenges for cancer services in most developed countries of the world (Davydov M.I., wolves S.M., Polotsk BE the Improvement of surgical treatment of patients with non-small cell lung cancer // ROS. on Oncology. Journe. - 2001. No. 5. - P.14-17; G.A. Novikov, Osipova N.A., starinsky CENTURIES, Prokhorov BM, Benenson LI, Gazizov AA Perspective what s the development and improvement of palliative care cancer patients in Russia // Russian medical journal, 1995, No. 1, - S-17; Trachtenberg AH, Chissov V.I. Clinical ecopolitology // M - 2000. - 599; Hansen N.N., Bunn R.A. Lung cancer therapy // Taylor&Francis. 2005. - P.100-105).
In recent years, medicine has been aware of the fact that the functional parameters (in the broad sense of the term) are important for evaluating the effectiveness of therapeutic techniques and predict disease outcome. Among these options is a special quality of life. This term, recently born in Western philosophy, has taken a significant place in sociology and medicine (G.A. Novikov et al. Prospects for the development and improvement of palliative care cancer patients in Russia // Russian medical journal, 1995, №1, - S-17; Merabishvili V.M. Malignancies in the world, Russia, St. Petersburg. - SPb., IPK BIONT", 2007. - 422; Chissov V.I., Novikov GA, Prokhorov BM Palliative care is one of prioritetnyh national Oncology // III Congress of Palliative medicine and rehabilitation in health care, Palliative medicine and rehabilitation, 2000, No. 1-2, - P.6).
The severity of the condition inoperable cancer patients and therefore a low quality of life, often due to their exudative pleurisy, and then the question arises about the need to eliminate to increase the respiratory surface, whether the eradicate compression of the lung and the mediastinum, effects of obstructive pneumonia, and often to be able to continue to conduct special cancer treatment.
Lung cancer is the main cause of malignant exudative pleurisy. He is one of the first places among the incidence of malignant neoplasms. In Russia he is in second place in the overall structure of oncological diseases and on the ground (31%) among malignant tumors in men. In Russia annually registers more than 63000 cases of lung cancer and dies from it to 60,000. In St. Petersburg also remains one of the highest levels of cancer incidence. Statistics show that lung cancer is one of the most common and is characterized by generally poor prognosis of cancer. According to various sources, the majority of patients (over 75%) is in specialized medical institutions in the III-IV stages of the disease. More than 50% of these patients the disease is accompanied by respiratory insufficiency, due to the presence of exudative pleurisy (Merabishvili V.M. Malignancies in the world, Russia, St. Petersburg. - SPb., IPK BIONT", 2007. - 419-422 S.; Landis S.H. et al. Cancer Statistics, 1999 // CA Cancer J Clin 1999; 49:8-31; Ling, S. et al. High-tech will improve radioterapy of nsclc: a hypothesis waiting to be validated // Int. J. Radiat. Oncol. Biol. Phys. - 2004. - Vol.60. - P.3-7; Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the Big Lung Trial. Eur J CardioThorac Surg. 2004; 26: 173-182). In addition to lung cancer secondary cancerous pericardial effusion can occur when common cancers breast cancer (45-50%), stomach (30-65%), thyroid (25-45%) and some other malignant tumors. About 2% of the total number of specific pleural effusions accounts for diffuse malignant pleural mesothelioma (Kolesnikov I.S., Lytkin M.I. Surgery of the lung and pleura // HP: Medicine, 1988. - 382 S.; MalcolmM. et al. The Role of Surgery in N2 Non-Small Cell Lung Cancer. Clin. Cancer Res. 2005; 11 (13 Suppl) 5033-5037; Rodriguez-Panadero F. // Monaldi Arch. Chest Dis. - 2000 Feb. - Vol.55(1). - P.17-19; J.H. Schiller et al. Comparison of outcome and patients characteristics in advanced NSCLC: analysis of ECOG 1980-2000 // Proc. ASCO. - 2002. - Vol.21. - P. 304f). Exudative pleurisy, or hydrothorax, is the result of increased capillary permeability in the tumor infiltration of the pleura, inflammation, irradiation, etc. Characteristic features of pleural effusion are the reduction of chest excursion and volume of breath expressed shortness of breath and pain. To prevent exudation of the traditionally used methods such as surgical (open and endoscopic) pleurectomy, chemical pleurodesis (intrapleural injection of Akrikhin, talc, tetracycline, delagila), fizi is a mini pleurodesis (electrocoagulation, argon plasma, laser, cryodestruction). Widespread intrapleural introduction of chemotherapeutic drugs such as cyclophosphamide, bleomycin, etc. However, the results of applying these methods has not been satisfactory. Physical and chemical pleurodesis can usually be achieved only partial effect is limited due to frequent obliteration of the pleural cavity, and the inaccessibility of many of its departments to conduct manipulations. High probability of resistance pleural effusions to intracavitary doing drugs (43-82% of cases) is also a frequent cause of re-accumulation abundant pleural effusion. In the foreign literature of recent years there are reports of the use of intrapleural hemoperfusion (intrathoracic chemohyperthermia - ITCH) with cisplatin and/or mitomycin. However, using this method in isolation is not allowed to reach the authors significant improvement in immediate and remote results (relapse accumulation of liquid more than 4%; the median survival of less than 5 months.) with a significant number of complications (30%) (O. Monneuse et al. Long-term results of intrathoracic chemohypertermia (ITCH) for the treatment of pleural malignancies // British J. of Cancer. - 2003; Vol.88. - P.1839-1843; De Bree, E. et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma // Chest. - 2002. - 121: 480-487; Yellin A. et al. Hyperthermic pleural perfusion with cisplatin: early clinical experience. Cancer. - 2001. - 92: 2197-2203).
In General, according to the reviewed literature, the use of the above-described isolated techniques allows to achieve complete cessation of accumulation of effusion in the pleural cavity is not more than 70-80% (Akopov A.A., Kondratyev V.B. have been Intracavitary application bleomitsetina with malignant pleurisy // Materials of the 3rd all-Russian oncological conference. SPb., - 1999. P.137-138; Moiseyenko VM Modern chemotherapy of disseminated breast cancer // Materials of the 3rd all-Russian oncological conference. SPb, - 1999. S-110; Hansen N.N., Bunn R.A. Lung cancer therapy // Taylor&Francis. 2005. - P.100-105; Sahn S.A. Pulmonary Emergencies // Churchill Livingstone, New York, 1982, c.295-299; Raftopoulas H. et al. Assessing the role of chemotherapy in advanced NSCLC: a comprehensive review of large, randomized trial 1991-2001 // Proc. ASCO. - 2002. - Vol.21. - P.322a). It is impossible not to take into account a large number of side effects and complications in the implementation of these techniques, such as allergic reactions, respiratory distress syndrome, development of system and multiple organ failure (J.R. Campos et al. Thoracoscopic pleurodesis with talc // Chest. - 2001 Mar. - Vol.119(3). - P.801-806; Furedi A. et al. Video thoracoscopic pleurodesis in the treatment of malignant pleural effusion // Acta Chir Hung. - 1999. No. 2. - Vol.55. - P.17-19; H.H. Hansen, P.A. Bunn Lung cancer therapy // Taylor&Francis. 2005. - P.100-105; Rodriguez-Panadero F. // Monaldi Arch. Chest Dis. - 2000 Feb. - Vol.55(1). - P.17-19).
In eticholeve become obvious advantages of the introduction of combined and complex methods of elimination of hydrothorax in malignant exudative pleurisy, to eliminate these deficiencies by complement effects. The analysis of literature data showed newness "of the Method of complex treatment of malignant neoplastic lesions of the pleura, accompanied by exudative pleurisy".
Closest to the proposed method are the previously proposed method, which consists in conducting argon plasma electrocautery pleura with the subsequent performance of intraoperative photodynamic therapy photosensitizer "photoditazine and radiation of a semiconductor laser wavelength of 662 nm, with the aim of reducing tumor mass, reduction of exudation and loss of protein, reducing inflammation, intoxication and pain syndrome (patent No. 2289352, publ. 20.12.2006, Bulletin No. 35).
The advantages of the combination of argon plasma electrocoagulation treatment with photodynamic therapy added effects caused by the conduct of hyperthermic intrapleural hemoperfusion cisplatin, in order to achieve maximum cytoreductive, termination exudation and protein loss, stop inflammation, tumor intoxication and pain syndrome due to local and systemic effects.
The technical result of this method is 1) reduction of the tumor mass (cytoreductive); 2) termination of exudation and loss of protein; 3) the reduction of inflammation, intoxication and pain syndrome; 4) local and systemic cytotoxic effects of cisplatin. This is achieved through argon plasma electrocautery pleura ("ERBOTOM ICC 300; ARS-300"; ICC "ERBE VIO" - "ERBE Elektromedizin", Germany) with subsequent intraoperative conducting photodynamic therapy and hyperthermic intrapleural hemoperfusion (perfusion pump "MARS", CNIRD, Russia; physiological perfusion unit-oxygenator "MINIMAX", "Medtronic, USA).
In the clinic of the research Institute of Oncology named New University used functional complex consisting of control unit and control organotitanium, a high-frequency generator and a flexible probe electrodes. In a functional complex had software with a choice of optimum parameters of the power generator and argon consumption, allowing you to precisely control the depth and amount of exposure. Argon plasma coagulation is a method of monopolar high-frequency electrosurgery, in which the energy of the high frequency current is transmitted to the tissue in a contactless manner by means of ionized argon. Argon plasma arc is formed between the electrode and the tissue that has the lowest resistance. The resulting dehydration (desiccation) of coagulated tissue increases its resistance that Pref is the CIO to move argon arc on a piece of tissue with less resistance, ensuring the homogeneity of the zone of coagulation and controllability of the depth of the impact. The depth of coagulation depending on the power and duration of application of the electrode does not exceed 3 mm, reducing the risk of damage to major vessels and organs of the thoracic cavity. Coagulation is carried out at a power of 60 to 90 watts, at a flow rate of argon at 2.0-2.4 l/min One advantage of this method is coagulation in an oxygen-free environment that allows you to affect the fabric without substantial charring (carbonization) and smoke pleural cavity.
For photodynamic therapy was used photosensitizer "photoditazine" (registration No. 249188) based on water-soluble form of chlorin E6 with a number of biological, physico-chemical and energy characteristics that distinguish it from previously used in the clinic photosensitizers, such as: 1) strong absorption band in the red wavelength region of the spectrum (662 nm); 2) rapid pharmacodynamics (time accumulation in the tumor is 2 hours, the time for complete removal from the body - 24-36 hours); 3) high affilinet (factor accumulation in the tumor compared with normal tissue 10:1-15:1); 4) low dark toxicity, providing ease of use in clinical and outpatient settings; 5) high luminous photocytotoxic is here, associated with the active generation of singlet oxygen (75-96%) when interacting with laser radiation; 6) highly penetrating into the tissue, as the wavelength of the laser lies in the area of their optical transparency; 7) large therapeutic range of the drug; 8) low allergenicity. The radiation produced by semiconductor laser "Atcus-2" (registration No. 29/05010104/5958-04 MH RF from 26.01.04.; certificate of conformity GREW RUIM) with a power density of 300 mW/cm2; the total power of the radiation - 400-j. The dose was 1.5 mg/kg of body weight. Irradiation of the tumor was performed 2 hours after administration of the drug (the drug was administered before the operation). In addition to wearing sunglasses during the day no other protective measures are not required. The introduction of photodithazine followed by laser irradiation did not cause common phototoxic reactions. In any case it is not marked for cumulative effect.
When conducting hyperthermic intrapleural hemoperfusion (perfusion pump "MARS", CNIRD, Russia; physiological perfusion unit-oxygenator "MINIMAX", "Medtronic, USA) was used cytotoxic drug cisplatin, bifunktionalno alkylating DNA, inhibiting the biosynthesis of nucleic acids in a dose of 100 mg dissolved in 1500-3000 ml of 0.9% solution of n is sodium chloride. Hyperthermic intrapleural hemoperfusion was carried out through a standard silicone drainage tube, supplied in the kit, at a temperature of 42°C for 60 min with a feed rate of solution of 1200 ml/min
All stages of treatment were carried out sequentially during a single surgical intervention in terms of General anesthesia, adelegate ventilation in the front-side or lateral position of the patient during videothoracoscopy or open transthoracic surgery. When installed passive pleural drainage for control of hemostasis and evacuation of fluid in the nearest postoperative period (1 to 3 days).
The study included data of 6 patients at the age from 35 to 63 years, 2 women and 4 men, which from April 2007 to February 2008 in our hospital conducted a comprehensive treatment of malignant neoplastic lesions of the pleura, accompanied by exudative pleurisy. In all cases produced morphological verification process. The described method of treatment used in two patients with dissemination of the tumor in the pleura in advanced non-small cell lung cancer and four patients with diffuse malignant mesothelioma of the pleura. All patients were able to achieve immediate persistent halt the accumulation of pleural effusion p is lost. The need for repeated surgical interventions and pleural punctures did not arise. All patients intervention was performed with palliative intent. Immediately after combined treatment of patients reported subjective improvement of health, which was confirmed and objective data physical examination, improvement in clinical, biochemical and gas blood tests, x-ray data.
Inventive step of the proposed method is confirmed by the fact that in all cases (100%; N=6) completely abolished the accumulation of pleural effusion, marked improvement of function of external respiration, reduced toxicity and pain. Cases of recurrent malignant pericardial effusion in patients not selected.
As clinical samples and to confirm the terms "industrial applicability", the following clinical observations.
Example 1. Patient WMA, 44 years. Complaints at admission to intensive pain in the chest on the left, short of breath with little exertion, weakness. Clinical diagnosis: diffuse malignant mesothelioma of the pleura on the left. Exudative pleurisy. The morphological examination (biopsy of the pleura) - epithelialization malignant mesothelioma. perezia 14.05.2007, videothoracoscopy left, argon plasma pleurodesis with intraoperative photodynamic therapy (photoditazine - 1.5 mg/kg; total power of the radiation - 400 j/cm2when the power density of 300 mW/cm2and hyperthermic intrapleural hemiberlesia cisplatin 100 mg in 3000 ml of 0.9% solution of sodium chloride at a temperature of 42°C for 60 min with a feed rate of solution of 1200 ml/min Duration is 60 minutes. Dynamic clinical and radiographic observation of the absence of recurrent exudative pleurisy for 10 months (the entire period of observation).
Example 2. Patient SLS, 59 years old. Complaints upon receipt of shortness of breath on exertion, dry cough, chest pain, weakness. Clinical diagnosis: Malignant diffuse-nodular pleural mesothelioma is right with these metastases. Exudative pleurisy. The morphological examination (biopsy of the pleura) - epithelialization malignant mesothelioma. Operation 24.06.2007, Right-sided thoracotomy, argon plasma pleurodesis with intraoperative photodynamic therapy (photoditazine - 1.5 mg/kg; total power of the radiation - 400 j/cm2when the power density of 300 mW/cm2and hyperthermic intrapleural hemiberlesia cisplatin 100 mg in 1600 ml of 0.9% sodium chloride solution at t is mperature 42°C for 60 min with a feed rate of solution of 1200 ml/min The procedure takes 45 minutes. Dynamic clinical and radiological observation no recurrence of exudative pleural effusion in 9 months (the entire period of observation).
Example 3. Patient FWA, 35 years. Complaints at admission at increasing temperature up to 39°C; shortness of breath with little exertion, weakness, cough with viscous sputum, hoarseness. Clinical diagnosis: Cancer of the right upper lobe bronchus with the transition to home and metastases in the lymph nodes of the root of the lung and mediastinum. Dissemination on the pleura. Exudative pleurisy. The morphological examination (biopsy of the pleura) - usernotification adenocarcinoma. Operation 16.07.2007, argon plasma pleurodesis with intraoperative photodynamic therapy (photoditazine - 1.5 mg/kg; total power of the radiation - 400 j/cm2when the power density of 300 mW/cm2and hyperthermic intrapleural hemiberlesia cisplatin 100 mg in 2500 ml of 0.9% solution of sodium chloride at a temperature of 42°C for 60 min with a feed rate of solution of 1200 ml/min Duration is 55 minutes. Dynamic clinical and radiographic observation of the absence of recurrent exudative pleurisy 8 months (the entire period of observation).
The method of complex treatment of malignant neoplastic lesions p is Evry,
accompanied by exudative pleurisy, including argon plasma electrocautery pleura when the power 60-90 W and the flow rate of argon at 2.0-2.4 l/min, followed by intraoperative photodynamic therapy with the drug, "photoditazine" 1.5 mg/kg and radiation of a semiconductor laser wavelength of 662 nm, power density
300 mW/cm2and the total dose of energy of 400 j/cm2, characterized in that it additionally produce hyperthermic intrapleural hemoperfusion cisplatin 100 mg 1500-3000 ml of 0.9%sodium chloride solution at a temperature of 42°C for 60 min with a feed rate of solution of 1200 ml/min
SUBSTANCE: preparation inhibiting malignant tumour development contains dis-A-fibrin and may inhibit malignant tumours by inhibiting distribution and migration of malignant tumour cells thereby may inhibit malignant tumour development.
EFFECT: inhibition of tumour invasion and dissemination.
8 cl, 4 ex, 2 tbl, 9 dwg
SUBSTANCE: 1-3-fold amount of water is added to mixed five-seven-year old ginseng with further treatment at pressure 1.20 to 1.50 kg/cm2 if ginseng is rind, or 2.30 to 3.00 kg/cm2 if ginseng is covered with rind at 110-130°C during 1 to 5 hours to produce treated ginseng thereafter extracted with mixed methanol and methylene chloride in ratio 0.6:1.40 to 1.2:0.8 by boiling extraction method with using a backflow condenser during 1 hour to approximately two days. The mixture is filtered that is followed with filtrate concentration and drying. The pharmaceutical composition for treatment or prevention of stomach, liver, lung, skin or breast cancer contains ginseng extract. Foodstuff contains ginseng extract.
EFFECT: product with high content of ginsenoside Rg5.
6 cl, 3 ex, 3 tbl, 14 dwg
FIELD: medicine; veterinary science.
SUBSTANCE: prevention of carcinogenic action of diethyl nitrosamine in experimental animals is ensured by daily introduction of anticarcinogen combined with feed. Anticarcinogen is presented with powdered phytoadaptogen "Chagovit" dosed 50 mg/kg within 9 months. On the 5th day, this therapy is added with introduction of diethyl nitrosamine combined with drink dosed 100 mg/l within the first 4 months.
EFFECT: lower rate of neoplastic changes in liver and oesophagus tissues, higher lifetime and survival rate of animals ensured by lower level of lipid peroxidation and improved activity of antioxidant enzymes.
2 ex, 2 tbl, 8 dwg
SUBSTANCE: there is disclosed pharmaceutical product as prepared solution. The pharmaceutical product comprises a reservoir filled with dissolved zoledronic acid or its pharmaceutically acceptable salt. At least the internal surface of said reservoir contains plastic material that is polyolefin. The product is exposed to thermal sterilisation, preferentially to moist thermal sterilisation. Besides the product can contain a buffer component, preferentially the buffer organic base. Additionally, the product can contain an isotonic component, preferentially mannitol. The invention provides product sterilisation at high temperature 121°C during 150 minutes without visible deformations and damages of sealed integral reservoir, as well as decomposition of pharmaceutical substance.
EFFECT: thermal stability allows for multiple sterilisation cycle that leads to sterility assurance level at least 10-12.
38 cl, 19 ex
SUBSTANCE: invention refers to medical products and concerns pharmaceutical composition for treatment of the diseases associated with urokinase activator of plasminogen (u-PA) and/or with receptor of activator of urokinase plasminogen (u-PAR), containing: (i) amidino-, hydroxyamidino-, guanydino- and/or hydroxyguanydinophenylalanine derivative as an active material, (ii) mixed alcohol and polyol, and (iii) aqueous phase containing buffer solution. There is also disclosed stabilisation method of pharmaceutical composition.
EFFECT: physical and chemical stability.
25 cl, 6 dwg, 1 tbl, 9 ex
SUBSTANCE: according to the invention, method involves introduction of Paramycin 42 ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779). In addition, the invention refers to applications of CCI-779 in producing a medicinal agent for amphicyte lymphoma.
EFFECT: application of the invention ensures amphicyte lymphoma treatment.
9 cl, 3 ex
SUBSTANCE: invention refers to medical products, particularly to application of compound of formula I where A stands for O, R stands for hydrogen or lower alkyl, and Z stands for O to prepare a medicinal agent for treatment of cancer disease chosen from primary cancer of Fallopian tube; primary peritoneal cancer and colorectal cancer progressing after Irinotecan therapy. Besides the invention concerns the pharmaceutical composition including specified compound, therapy of specified diseases and commercial package. formula (I).
EFFECT: agent is characterised with improved effectiveness.
13 cl, 7 ex
SUBSTANCE: there is described oral pharmaceutical composition containing 9,10-dehydroepothilone combined with a pharmaceutically acceptable carrier. According to the second version, the oral pharmaceutical composition contains trans-9,10-degihydroepothilone D and a pharmaceutically acceptable carrier containing hydroxypropyl-β-cyclodextrine, ethanol and propylene glycol. The concentrate for injection contains 9,10-degihydroepothilone D in the pharmaceutically acceptable carrier.
EFFECT: good bioavailability of epothilone D.
21 cl, 4 ex
SUBSTANCE: prevention of carcinogenic action of diethyl nitrosamine in experimental animals is ensured by introduction of kaskorutol dosed 0.4 g/kg within 9 months as an anticarcinogen, while diethyl nitrosamine is introduced in a dose 100 mg/l 5 days after introduction of kaskorutol within 4 months.
EFFECT: reduced carcinogenic action of diethyl nitrosamine due to inhibition of blastomogenic process, lowered level of lipid peroxidation, improved activity of antioxidant enzymes.
2 tbl, 8 dwg, 1 ex
SUBSTANCE: antineoplastic preparation which coordination compound on the magnesium gluconate base wherein the ligands are chosen from the group consisting of γ-aminobutyric acid (GABA), 3-hydroxy-GABA, ethylendiaminotetraacetic acid and ethylenglycoltetraacetic acid or binary salt chosen from the group consisting of magnesium butyrogluconate, oxymagnesium butyrogluconate, magnesium glucarate-gluconate, calcium butyrogluconate, calcium oxybutyrogluconate, calcium glucarate-gluconate and their combinations.
EFFECT: claimed preparations exert the apoptotic and antiproliferative effect retaining the civilised cells.
4 cl, 1 tbl, 2 ex
SUBSTANCE: therapy involves exposure on acupunctural points of gall bladder in combination with conventional conservative therapy. Exposure on acupunctural points implies laser radiation of frequency 1425-1575 Hz, wavelength 0.83-0.89 mcm, unit impulse power 5-6 Wt, unit impulse duration 110-160 ns. Acupunctural points are tonic by exposure within 4-6 seconds, while sedation is ensured by exposure within 16-18 seconds. Then right hypochondrium is exposed to pulse magnetic field of induction 22.5-37.5 mTl, frequency 49.5-50.5 Hz, duration 20-25 minutes. The epigastrium is exposed to variable magnetic field of induction 22.5-37.5 mTl, frequency 49.5-50.5 Hz, and duration 20-25 minutes. The therapeutic course is 10-12 days.
EFFECT: method reduces fatal outcome rate ensured by exacerbation management and elective surgery.
2 ex, 3 tbl
SUBSTANCE: said device contains a transparent cylindrical support case, a retainer ring and a lock nut. The support case comprises a necked top with an external thread and a light guide port, and a hollow bottom with a circular marking edge at the end face. When the device is applied for photodynamic therapy of intraocular neoplasms, the marking edge is covered with brilliant green. The device is mounted with its end face of the bottom with a marking edge on sclera exposed to contact transscleral laser irradiation herewith covering the adjacent fields by 15-20% of the area through sequential relocation of the device from periphery to the middle within projection of tumour base on sclera and covering 2 mm of adjacent tissues.
EFFECT: application of group of inventions provides limitation of the area of one laser radiation spot in specified dimensions, herewith maintaining constant distance of the light guide end face to irradiated surface within procedure, accurate visualisation of the irradiated sites, with limiting the area of a laser irradiation by desired region.
2 cl, 1 dwg
SUBSTANCE: invention concerns medicine, particularly obstetrics and hestosis treatment for the pregnant. Method involves endovascular laser irradiation of blood for six days. Further, polyphepan is administered internally for eight days in the dosage of 0.5 g per kg of pregnant body weight for 3-4 times per day.
EFFECT: therapeutic effect with reduced treatment duration and medication load on organism of the pregnant due to the selected regimen.
SUBSTANCE: invention concerns medicine, laser medicine, and can be applied in treatment of trophic ulcers of venous etiology. Method involves processing of ulcer surface and skin around ulcer by air and gas flow with nitrogen oxide content 2000 ppm or more at 40°C, with 10 second exposition per 1 cm2. Further, 0.1% Radachlorine gel is applied as photo sensitiviser in amount of 0.2 g per 1 cm2 with 60 minutes exposition. Then laser emission of 0.665 mcm wavelength and light energy dosage of 150-200 J/cm2 is applied at 3-5 mm distance from wound surface. Afterwards intravenous blood irradiation is performed over cubital vein by laser emission of 0.632 mcm wavelength and radiation power of 5 mW with 15 minutes exposition. Treatment course comprises 10 daily procedures of air and gas flow processing and intravenous blood irradiation and 5-8 photodynamic therapy procedures performed over 2 day interval.
EFFECT: improved neurotrophic regulation of damaged tissues, antimicrobe effect, reduced frequency of purulent complications, improved blood flow properties, prevented resistance of ulcer microflora to antibiotics and drugs, prevented dysplasia, cicatrical changes and skin malignisation around trophic ulcer.
4 cl, 1 ex
FIELD: medical equipment.
SUBSTANCE: invention concerns medical equipment and can be applied in cancer tissue treatment in various organs of biological objects. Device includes semiconductor laser diode, clock generator, semitransparent mirror, comparator, first, second and third direct current amplifiers, differentiating amplifier, discriminating amplifier, first and second photo receivers, delay line, analog to digital converter, programmed permanent memory, first and second binary code comparators, first and second control systems of secondary power sources, first and second secondary power sources and light panel/indicator. Biological object is positioned in line between semiconductor laser, semitransparent mirror and second photo receiver.
EFFECT: extended range of technical devices for laser cancer therapy.
SUBSTANCE: invention refers to medicine, namely to laser therapy. The first stage of the therapy involves introduction of medicines and intravenous laser blood exposure by installing a needle in one solution transfusion system for quartz fibre of diametre 0.7 mm through which the patient is exposed to helium-neon laser of power 1.2 mW at exposition 90 minutes within seven daily procedures. The second stage includes paravertebral block within herniated disk localisation in projection of herniated disk. Quartz fibre of diametre 0.7 mm is introduced through a puncture needle to the level of surface musculofascial layer. Injection of solution is immediately followed with irradiation with helium-neon laser of power 1.2 mW at exposition 80 minutes within seven daily procedures. Medicines within solution transfusion system are as follows: Trental 5 ml, Actovegin 5 ml, 15% Xantinol Nicotinate 2 ml, vitamin B1 2 ml alternated with vitamin B6 2 ml, 5% vitamin C 3 ml dissolved in physiologic saline 150 ml. Paravertebral block of the first day includes 5% glucocorticoid Diprospan 1 ml combined with 2% Lidocaine. For the following days 2% Lidocaine is used.
EFFECT: method allows terminating inflammatory process, ensuring stable pain management.
SUBSTANCE: therapy of secondary lower limb lymphodema refers to medicine, namely to clinical lymphology. The oatient is exposed to laser light of wavelength 0.6328 mcm combined with intravenous laser irradiation of power 1.2 mW and exposition 90 minutes and intravenous introduction of medicine solutions: Trental, Actovegin, Pheopolyglukine, vitamin B, C complexes, 0.15% xantinol nicotinate. Procedures are daily at seven procedures per course.
EFFECT: therapy provides stable reduction of secondary lower limb lymphodema without therapeutic by-effects, prevents recurrence.
2 cl, 2 ex
SUBSTANCE: invention refers to medicine, to neurology. The therapy involves taking the medicines improving cerebral blood circulations. Pharmacotherapy is combined with exposure to laser light within anconeus and popliteal fold regions. Laser puncture covers the points VB 20 and VB 21 symmetrically downright. Laser light is characterised with wavelength 0.89 mcm, power 3 mW and frequency 600 Hz. Herewith light exposure is 1 minute per each point and 2-3 minutes per elbow and popliteal folds. Therapeutic course is 10 days twice every second month.
EFFECT: method reduces treatment time.
3 ex, 1 tbl
SUBSTANCE: invention relates to medicine, oncology, surgery, radiology, physical therapy and can be used for treating patients with larynx cancer. Area of radiation and surrounding tissues is exposed to infrared laser irradiation. From first day of radioreaction diagnostics, exposure to infrared laser irradiation with constant magnetic field with magnetic induction intensity within 20 mTa, recurrence frequency of pulse laser irradiation of infrared spectrum within 80 Hz, power 0.5-1.0 W on all zone of irradiation is performed with defocused ray for 30-120 seconds. Course includes 3-8 procedures with further application on irradiation zones and intake of a teaspoon of cedar nut oil and before going to bed daily during the whole course of radiation therapy.
EFFECT: method allows to increase efficiency of treatment of early radioreactions and prevent development of later radiation damage reducing severity and frequency of their development.
SUBSTANCE: invention relates to field of medicine, namely to ophthalmology. Laser stroboscopy is carried out during 5 days, 2 times a day with 1 hour interval. First 10 minutes each eye is influenced in turn, then for 5 minutes both eyes are influenced simultaneously. Distance to speckle is 1 m.
EFFECT: recovering binocular functions with elimination of anisoaccomodation, enhancing binocular interaction, increasing visual acuity.
3 cl, 2 ex
SUBSTANCE: method is implemented as follows: bacterial-enzymatic probiotic "Balance-narine-f" is introduced locally and orally in combination with inhalation of negative air ions.
EFFECT: allows for decrease of complications and higher efficiency of treatment.
1 tbl, 3 ex